Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer

NCT ID: NCT00003434

Last Updated: 2014-02-10

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1998-06-30
• Study Completion Date: 2002-08-31

Brief Summary

Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA.

Purpose: Phase II trial to study the effectiveness of white blood cells plus carcinoembryonic antigen peptide-1 in treating patients with stage I, stage II, or stage III pancreatic cancer that has been surgically removed.

Detailed Description

Objective: I. Perform a pilot study of active immunotherapy with autologous dendritic cells pulsed with the CEA peptide, CAP-1, after surgical resection in patients with CEA expressing pancreatic cancer. II. Perform laboratory analysis to monitor the presence, persistence, and function of CAP-1 specific T-cells in this patient population.

Outline: Patients undergo leukapheresis for up to 4.5 hours prior to vaccination. Half of the collected dendritic cells are pulsed with carcinoembryonic antigen (CEA) peptide and the other half are pulsed with hepatitis B antigen peptide (HBsAg). Equal doses of CEA and HBsAg peptide pulsed dendritic cells are administered intravenously over 3 minutes every 4 weeks for a total of 6 doses each. Patients undergo a second leukopheresis 2 weeks after the last dose of immunotherapy to obtain specimens for immunologic tests. Patients are followed at weeks 22, 36, 48, and every 6 months thereafter.

Project Accrual: A total of 24 patients will be accrued for this study over 2 years.

Conditions

Pancreatic Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

carcinoembryonic antigen peptide 1

Intervention Type: BIOLOGICAL

hepatitis B antigen peptide

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Disease Characteristics:

• Histologically confirmed stage I, II, or III adenocarcinoma of the pancreas Resected with no gross residual disease At least 50% of tumor cells must be CEA positive and stain with at least moderate intensity HLA-A2 positive

Patient Characteristics:

• Age: 18 and over
• Performance status: Karnofsky 70-100%
• Life expectancy: Greater than 6 months
• Hematopoietic: Absolute neutrophil count at least 1000/mm3
• Hepatic: Bilirubin less than 2.0 mg/dL SGOT and alkaline phosphatase less than 4 times the upper limit of normal No hepatic failure
• Renal: Creatinine less than 2.0 mg/dL OR Creatinine clearance greater than 50 mL/min
• Cardiovascular: No New York Heart Association class III or IV heart disease
• Pulmonary: No concurrent asthma or chronic obstructive pulmonary disease

Other:

• No other malignancy except nonmelanoma skin cancer or controlled superficial bladder cancer within the past 5 years.
• No history of autoimmune diseases such as inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, rheumatoid arthritis, or multiple sclerosis
• No active acute or chronic infection such as urinary tract infection, HIV, or viral hepatitis
• No active infectious enteritis or eosinophilic enteritis Not pregnant or nursing Fertile patients must use effective contraception

Prior Therapy:

• Biologic therapy: At least 4 weeks since immunotherapy. No other concurrent immunotherapy
• Chemotherapy: At least 4 weeks since chemotherapy and recovered. No concurrent chemotherapy
• Endocrine therapy: No concurrent corticosteroid or immunosuppressive therapy. At least 6 weeks since steroid therapy
• Radiotherapy: At least 4 weeks since radiotherapy and recovered
• Surgery: Recovered from prior surgery

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Duke University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael A. Morse, MD

Role: STUDY_CHAIR

Duke University

Locations

Duke Comprehensive Cancer Center

Durham, North Carolina, United States

Countries

United States

Other Identifiers

DUMC-97093

Identifier Type: -

Identifier Source: secondary_id

NCI-G98-1457

Identifier Type: -

Identifier Source: secondary_id

CDR0000066460

Identifier Type: OTHER

Identifier Source: secondary_id

1259

Identifier Type: -

Identifier Source: org_study_id